Verifying…
Home / Drug A–Z / AFRIGENERICS PREGABALIN CAPSULES 150MG $

AFRIGENERICS PREGABALIN CAPSULES 150MG $

NAFDAC Reg. No. A4-102037 · Drug

Registered with NAFDAC — registration activeAs of 5 November 2026 · synced automatically from official sources.
Product
AFRIGENERICS PREGABALIN CAPSULES 150MG $
NAFDAC number
A4-102037
Active ingredient
Pregabalin
Strength
150mg
Form
Capsule
Pack size
3 X 10 Capsules
Manufacturer
Not listed
Applicant (holder)
AFRIGENERICS PHARMACEUTICALS LTD
Approved
31 Mar 2026
Status
Active View on NAFDAC ↗
Registration valid to
30 Mar 2031
WHO alerts
None found
Community reports
None
Times checked
0

RxVerify commentary

  • AFRIGENERICS PREGABALIN CAPSULES 150MG $ is on the NAFDAC register with an active registration (A4-102037). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. Not medical advice — always follow your doctor or pharmacist.

What AFRIGENERICS PREGABALIN CAPSULES 150MG $ is used for

From the official U.S. FDA label for pregabalin, the active ingredient registered with NAFDAC.

What it is used for

Pregabalin capsules are indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury Pregabalin capsules are indicated for: Neuropathic pain associated with diabetic peripheral neuropathy (DPN) (1 ) Postherpetic neuralgia (PHN) (1) Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older ( 1) Fibromyalgia ( 1) Neuropathic pain associated with spinal cord injury (1 )

Possible side effects

The following serious adverse reactions are described elsewhere in the labeling: Angioedema [see Warnings and Precautions (5.1) ] Hypersensitivity [see Warnings and Precautions (5.2) ] Suicidal Behavior and Ideation [see Warnings and Precautions (5.3) ] Respiratory Depression [see Warnings and Precautions (5.4) ] Dizziness and Somnolence [see Warnings and Precautions (5.5) ] Increased Risk of Adverse Reactions with Abrupt or Rapid Discontinuation [see Warnings and Precautions (5.6) ] Peripheral Edema [see Warnings and Precautions (5.7) ] Weight Gain [see Warnings and Precautions (5.8) ] Tumorigenic Potential [see Warnings and Precautions (5.9) ] Ophthalmological Effects [see Warnings and Pre …

Do not use if

Pregabalin capsules are contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy [see Warnings and Precautions (5.2) ] . Known hypersensitivity to pregabalin or any of its components. ( 4 )

Warnings

Angioedema (e.g., swelling of the throat, head and neck) can occur, and may be associated with life-threatening respiratory compromise requiring emergency treatment. Discontinue pregabalin immediately in these cases. ( 5.1 ) Hypersensitivity reactions (e.g., hives, dyspnea, and wheezing) can occur. Discontinue pregabalin immediately in these patients. ( 5.2 ) Antiepileptic drugs, including pregabalin, increase the risk of suicidal thoughts or behavior. ( 5.3 ) Respiratory depression: May occur with pregabalin, when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. Monitor patients and adjust dosage as appropriate. …

Pregnancy & breastfeeding

IN SPECIFIC POPULATIONS Lactation: Breastfeeding is not recommended. ( 8.2 ) 8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to pregabalin during pregnancy. …

General information only — not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of AFRIGENERICS PREGABALIN CAPSULES 150MG $

Add the expiry date printed on your pack for a full Trust Score — or look up uses, side effects and cheaper generics.

3 free checks left today · no signup Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About AFRIGENERICS PREGABALIN CAPSULES 150MG $

What is in AFRIGENERICS PREGABALIN CAPSULES 150MG $?

AFRIGENERICS PREGABALIN CAPSULES 150MG $ contains Pregabalin (150mg), as capsule, according to its NAFDAC registration record.

Is AFRIGENERICS PREGABALIN CAPSULES 150MG $ registered with NAFDAC?

Yes. AFRIGENERICS PREGABALIN CAPSULES 150MG $ is listed on the NAFDAC register under registration number A4-102037, and its registration is active as of 5 November 2026.

Has AFRIGENERICS PREGABALIN CAPSULES 150MG $ been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches AFRIGENERICS PREGABALIN CAPSULES 150MG $ in our automatically synced alert list.

How can I check that my pack of AFRIGENERICS PREGABALIN CAPSULES 150MG $ is genuine?

Run a free authenticity scan with the NAFDAC number A4-102037, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is AFRIGENERICS PREGABALIN CAPSULES 150MG $ used for?

Pregabalin capsules are indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury Pregabalin capsules are indicated for: Neuropathic pa (Summarised from the official U.S. FDA label for pregabalin. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used AFRIGENERICS PREGABALIN CAPSULES 150MG $? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from RxVerify users, not medical advice. Report side effects to your doctor and to NAFDAC.